Back to top

MS treatment announcement from PBAC

29 October 2020

The Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Australian Government about the medicines for subsidy through the Pharmaceutical Benefits Scheme (PBS).

At an “out-of-session” meeting in September 2020, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of ozanimod (brand name Zeposia®) for the treatment of relapsing remitting MS (RRMS).

Ozanimod, a capsule taken once daily, works by stopping some white blood cells from reaching the central nervous system (the brain, spine and optic nerve), where they can cause inflammation and damage, helping to protect against attacks on the nerves, and reducing inflammation and damage to the nerves’ protective coating thus slowing down the progression of disability.

To read the outcome in full, please visit:

To read a fact sheet about ozanimod (Zeposia®), please visit:

Recommendations by the PBAC are subject to final approval by the Australian Government.  We will keep you posted about any developments.

Always speak to your neurologist about what treatment best suits your individual circumstances.